Connection

W. Garvey to Overweight

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Overweight.
W. Garvey
Connection Strength
6.061
Overweight
  1. Two-year effect of semaglutide 2.4?mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023 03; 31(3):703-715.
    View in: PubMed
    Score: 0.765
  2. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
    View in: PubMed
    Score: 0.751
  3. Long-term health benefits of intensive lifestyle intervention in the Look AHEAD study. Obesity (Silver Spring). 2021 08; 29(8):1242-1243.
    View in: PubMed
    Score: 0.688
  4. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 05; 43(5):1085-1093.
    View in: PubMed
    Score: 0.627
  5. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med. 2016 Aug; 128(6):591-7.
    View in: PubMed
    Score: 0.487
  6. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.
    View in: PubMed
    Score: 0.393
  7. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
    View in: PubMed
    Score: 0.354
  8. Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. J Am Heart Assoc. 2023 Feb 21; 12(4):e027693.
    View in: PubMed
    Score: 0.192
  9. Burden of illness associated with overweight and obesity in patients hospitalized with COVID-19 in the United States: analysis of the premier healthcare database from April 1, 2020 to October 31, 2020. J Med Econ. 2023 Jan-Dec; 26(1):376-385.
    View in: PubMed
    Score: 0.191
  10. Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes Obes Metab. 2022 08; 24(8):1411-1422.
    View in: PubMed
    Score: 0.183
  11. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
    View in: PubMed
    Score: 0.178
  12. Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply. JAMA. 2021 09 28; 326(12):1214-1215.
    View in: PubMed
    Score: 0.175
  13. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.169
  14. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. Obesity (Silver Spring). 2018 02; 26(2):332-339.
    View in: PubMed
    Score: 0.136
  15. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.127
  16. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.122
  17. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring). 2016 Feb; 24(2):516-25.
    View in: PubMed
    Score: 0.117
  18. Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity (Silver Spring). 2015 Jul; 23 Suppl 2:S1-S26.
    View in: PubMed
    Score: 0.113
  19. Dietary adherence during weight loss predicts weight regain. Obesity (Silver Spring). 2011 Jun; 19(6):1177-81.
    View in: PubMed
    Score: 0.083
  20. Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008 Jan; 57(1):1-8.
    View in: PubMed
    Score: 0.067
  21. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 02; 25(2):468-478.
    View in: PubMed
    Score: 0.047
  22. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.039
  23. APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS. Endocr Pract. 2018 Jan; 24(1):6-13.
    View in: PubMed
    Score: 0.033
  24. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.